The aim was to evaluate the safety and lipid-altering efficacy in subjects with severe hypertriglyceridemia of an investigational pharmaceutical omega-3 free fatty acid ( OM3-FFA ) containing eicosapentaenoic acid and docosahexaenoic acid .